Search published articles


Showing 3 results for Damavandi

Abolfazl Kalantari , Farhad Zaker, Shahla Ansari Damavandi , Heydar Sharafi , Seyed Amir Yazdanparast ,
Volume 8, Issue 5 (1-2015)
Abstract

Background and Aim: Acute lymphoblastic leukemia patients show differences in serum levels and toxicity associated with methotrexate after its treatment. Pharmacogenetics is an important determining factor for these differences. In this study, the effect of +452 C / T and -401C / T polymorphisms of GGH gene on serum levels and toxicity associated with methotrexate was studied. The aim of this study was to evaluate the effect of +452C / T and -401C / T polymorphisms of GGH gene on methotrexate level in serum and its associated toxicity in patients with acute lymphoblastic leukemia. Furthermore, the frequency of the above polymorphisms was investigated for the first time in Iran.

Materials and Methods: The prevalence of these polymorphisms was assessed in 83 Iranian patients with ALL using PCR and RFLP. The relationship between the polymorphism and serum methotrexate levels and its toxicity was estimated by calculating the Odds Ratio.

Results: No correlation was found between +452CT polymorphism and serum levels of methotrexate and methotrexate-related toxicity. -401CT polymorphism was found to be correlated with methotrexate-related toxicity leading to thrombocytopenia (95% CI= 0.009-0.019, odds ratio=0.265) and leukopenia (95% CI = 0.021-0.042, odds ratio = 2.182) in consolidation phase of the treatment.

Conclusion: Evaluation of patients for methotrexate-related polymorphism of GGH gene may be useful in selecting the appropriate dose of methotrexate and reducing the toxic side effects associated with its administration.


Maliheh Javadi-Arjmand, Elia Damavandi, Hamid Choobineh, Majid Kabuli, Mohsen Ghadami,
Volume 18, Issue 3 (7-2024)
Abstract

Background and Aim: Follicle stimulating glycoprotein hormone (FSH) exerts its functions through its receptor (FSHR). In women of reproductive age, this hormone causes the growth and development of follicles in the ovary during the follicular phase of the menstrual cycle. This hormone is widely used in the treatment of infertility. Several polymorphisms have been reported so far in the FSHR gene, which are effective in the ovarian response, but the FSHR gene has two very common single nucleotide polymorphisms at positions 680 and 307 in exon 10. One of them at position 307 changes the amino acid threonine to alanine and the other at position 680 changes asparagine to serine. The polymorphism at position 307 of exon 10 is in the extracellular region of the receptor and the binding site of the hormone, which can be affected in response to internal and external FSH stimulation. These two SNPs have been reported to be associated with various ovarian responses and IVF outcomes in different populations. Different studies have particularly focused on rs6166 (p. Asn680Ser), but this study was conducted to investigate the possible association between rs6166 and rs6165 (p. Thr307Ala) and the IVF outcome.
Materials and Methods: After blood sampling and DNA extraction, the two polymorphisms in exon 10 of FSHR gene were analyzed using PCR-RFLP method in 120 women randomly assigned to two equal groups including IVF successful and IVF unsuccessful infertile women. The selection of patients to enter the study as well as the criteria for successful IVF are described in the text. In order to confirm the results, DNA sequencing was done for some selected samples. Finally, the results were analyzed using SPSS software.
Results: No significant differences were found in either SNPs between successful IVF and unsuccessful IVF patients in allelic frequencies (P-value>0.05).
Conclusion: Despite the different results of the studies conducted regarding the effect of FSHR gene polymorphisms (rs6165 and rs6166) in different populations, considering the lack of significant difference in the frequency of the above polymorphisms in the studied population, it is concluded that these two polymorphisms cannot be used to predict the outcome of IVF in Iranian infertile women.

Saber Yazdani Damavandi, Tayebeh Baniasadi, Mohammad Ali Molavi, Farid Khorrami,
Volume 19, Issue 5 (12-2025)
Abstract

Background and Aim: Cancer has been recognized as the second leading cause of child mortality in recent years. Due to the increasing amount of healthcare data for cancer patients, healthcare providers need a tool to monitor patients for immediate intervention. An intelligent and dynamic information management dashboard is capable of compiling and displaying data using charts and tables. In the present study, a management dashboard was designed for the oncology department of a children’s hospital, and its usability was evaluated.
Materials and Methods: This developmental–applied research was conducted in 2024 at the Educational, Medical, and Research Center for Children in Bandar Abbas. In order to create a management dashboard for the pediatric oncology department, three stages were carried out. In the first stage, all necessary content to be displayed on the dashboard was extracted based on a review of literature and documents from the oncology department of Bandar Abbas Children’s Hospital. This content was then validated by experts using the Delphi method in two rounds. In the second stage, a prototype of dashboard for the oncology ward was designed using Power BI Desktop software. Finally, its usability was evaluated using a SUS questionnaire by 20 users. The data were analyzed using descriptive statistics with SPSS software.
Results: Following the screening of 3,435 initial records and a review of 22 articles alongside 38 patient files, a preliminary set of 104 managerial and 67 clinical indicators was extracted. These indicators were validated through a tworound Delphi process with 12 experts, resulting in the final selection of 105 managerial and 71 clinical indicators for dashboard inclusion. Based on this validated set, a tenpage managerial dashboard was developed to present key performance metrics. Usability assessment using the System Usability Scale (SUS) yielded a mean score of 75.87, which, according to the Bangor scale, is classified as “acceptable” and corresponds to a grade of “excellent.” User feedback informed subsequent refinements to the dashboard’s data visualizations and interface. In summary, the developed dashboard represents an effective and userfriendly tool for monitoring and managing information within a pediatric oncology department.
Conclusion: The pediatric oncology management dashboard facilitates the integration and summarization of essential data for healthcare providers, thereby assisting them in making timely diagnoses and interventions for children with cancer. Additionally, the present dashboard demonstrates appropriate usability, which enhances users’ understanding of health information and leads to more accurate decision-making.


Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by: Yektaweb